The values and personal values received in television: a study with teenagers

En este trabajo se presentan los resultados obtenidos en una muestra 823 adolescentes de la Comunidad Autónoma Vasca acerca de la relación que existe entre sus valores personales y los valores percibidos en los programas de televisión que más les gustan. El marco teórico para la conceptualización y evaluación de los valores es el modelo de Schwartz, y el instrumento utilizado una escala de elaboración propia (Val TV 0.1) validada estadísticamente mediante el análisis multidimensional. De acuerdo a nuestras hipótesis, basadas en estudios previos, se puede afirmar que, en general, los sujetos tienden a percibir en los programas televisivos aquellos valores que ellos mismos manifiestan.This paper presents the results obtained from a sample of 823 adolescents from the Basque Autonomous Region regarding the relationship between their personal values and the values perceived in their favorite television programs. The theoretical framework used for conceptualizing and assessing said values was the Schwartz model, and the instrument used for the study was a scale developed by the authors (Val-TV 0.1), which was statistically validated using multidimensional analysis. In accordance with our hypotheses, which are based on previous studies, we can affirm that, in general, subjects tend to perceive in television programs those values that they themselves profess

Selective PARP-2 targeted therapy as a new strategy in pancreatic cancer: Beyond personalized medicine

Trabajo presentado en el 2nd Annual Congress of Conexión Cáncer, celebrado en Benidorm (España), del 23 al 25 de enero de 2023Pancreatic ductal adenocarcinoma (PDA) has been predicted to soon become the second leading cause of cancer related deaths. Although poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) have emerged as promising anti-cancer drugs for BRCA mutated tumors, in pancreatic cancer, phase III clinical results have failed. Major limitations of PARPi are due to their lack of selectivity. In this regard, we have recently demonstrated that Parp-2, but not Parp-1, plays a specific role in replicative stress, which is a known PDA hallmark. Therefore, we hypothesized that Parp-2 may represent a new potential target to fight against PDA. Importantly, Parp-2 genetic deletion in Ela-myc transgenic mice resulted in a 43% increase in animal survival. Tumor histopathological characterization showed that Parp-2 inhibition hampers acinar-to- ductal metaplasia, a key event in pancreatic cancer initiation. Parp-2 loss in vitro significantly decreased tumoroid generation capacity and induced DNA damage accumulation, increasing replicative stress and apoptosis. Molecular analysis of Ela-myc:Parp-2-/- vs Ela-myc Parp- 2+/+ pancreatic tumors in preneoplastic lesions, indicated that Parp-2 inhibition resulted in a less immune-evasive environment. Moreover, GSEA at late tumor stages shows p53 pathway enrichment in Ela-myc Parp-2+/+ vs Ela-myc:Parp-2-/-. Indeed, p53 inactivation was found in primary cell lines established from late stage Ela-myc:Parp-2-/- tumors, suggesting that loss of function of this pathway is required for tumor progression in the absence of Parp-2. Altogether our data highlight that Parp-2 is a novel target in pancreatic cancer and open new avenues for therapeutic intervention against this aggressive tumor by using specific Parp-2 pharmacological inhibitors

Targeting hypersialylation in pancreatic ductal adenocarcinoma to reverts their malignant phenotype

Trabajo presentado en el 15th Jenner Glycobiology and Medicine Symposium, celebrado en Oporto (Portugal), del 14 al 16 de junio de 202

Long-term safety of OnabotulinumtoxinA treatment in chronic migraine patients: a five-year retrospective study

Background: Real-world studies have shown the sustained therapeutic effect and favourable safety profile of OnabotulinumtoxinA (BoNTA) in the long term and up to 4 years of treatment in chronic migraine (CM). This study aims to assess the safety profile and efficacy of BoNTA in CM after 5 years of treatment in a real-life setting. Methods: We performed a retrospective chart review of patients with CM in relation to BoNTA treatment for more than 5 years in 19 Spanish headache clinics. We excluded patients who discontinued treatment due to lack of efficacy or poor tolerability. Results: 489 patients were included [mean age 49, 82.8% women]. The mean age of onset of migraine was 21.8 years; patients had CM with a mean of 6.4 years (20.8% fulfilled the aura criteria). At baseline, patients reported a mean of 24.7 monthly headache days (MHDs) and 15.7 monthly migraine days (MMDs). In relation to effectiveness, the responder rate was 59.1% and the mean reduction in MMDs was 9.4 days (15.7 to 6.3 days; p < 0.001). The MHDs were also reduced by 14.9 days (24.7 to 9.8 days; p < 0.001). Regarding the side effects, 17.5% experienced neck pain, 17.3% headache, 8.5% eyelid ptosis, 7.5% temporal muscle atrophy and 3.2% trapezius muscle atrophy. Furthermore, after longer-term exposure exceeding 5 years, there were no serious adverse events (AE) or treatment discontinuation because of safety or tolerability issues. Conclusion: Treatment with BoNTA led to sustained reductions in migraine frequency, even after long-term exposure exceeding 5 years, with no evidence of new safety concerns

Revealing prevalent cancers by interrogating glycoproteins with sustainable immunoelectrochemical tools

Trabajo presentado en el 4th European Biosensor Symposium, celebrado en Aquisgrán (Alemania), del 27 al 30 de agosto de 2023Introduction. The worldwide incidence and death toll of colorectal and pancreatic cancers (CRC and PDAC) have increased considerably since 1990. For this reason, both early detection and regular follow-up are considered key factors in improving patient prognosis. In this sense, the determination of the total content of specific proteins and their aberrantly glycosylated fraction in oncologic processes could help to achieve the proposed goals. Results and Discussion. In this work, two simple but highly competitive electrochemical immunoplatforms for the determination of total and glycosylated post-translational modified haptoglobin (Hp) [1], and CA19-9 [2] (candidate biomarkers associated with colorectal and pancreatic cancer, respectively) are presented. As seen in Figure 1, these biotools are uplifted in the use of magnetic immunocaptors and another antibody or a lectin as detector elements lastly labeled with HRP, which enables subsequent amperometric detection. The presented bioplatforms exhibit attractive characteristics in terms of simplicity, affordability, and point-of-care application compared to the conventional available methodologies, highlighting low detection limits (0.07 and 0.46 ng mL¿1 for total and glycosylated Hp, respectively, and 1.5 U mL¿1 for CA19-9), and short assay times (< 2 h). The workability of these quantitative bioplatforms for the analysis of secretomes from cultured CRC cells with the distinct potential to metastasize (Hp) or serum samples from healthy and PDAC-diagnosed subjects (CA19-9) was assessed to definitely confirm full exploitation of all the above exposed enticing attributes. Conclusions. Our findings clearly revealed the unquestionable ability of these modern electrochemical immunoplatforms to discriminate between healthy and cancer-diagnosed subjects, as well as to assess disease progression, positioning these simple but effective methodologies as advanced electroanalytical tools with proven real biomedical applications, and the hope of aiding in the accurate diagnosis of prevalent and high mortality cancers

Long-term platinum-based drug accumulation in cancer-associated fibroblasts promotes colorectal cancer progression and resistance to therapy

A substantial proportion of cancer patients do not benefit from platinum-based chemotherapy (CT) due to the emergence of drug resistance. Here, we apply elemental imaging to the mapping of CT biodistribution after therapy in residual colorectal cancer and achieve a comprehensive analysis of the genetic program induced by oxaliplatin-based CT in the tumor microenvironment. We show that oxaliplatin is largely retained by cancer-associated fibroblasts (CAFs) long time after the treatment ceased. We determine that CT accumulation in CAFs intensifies TGF-beta activity, leading to the production of multiple factors enhancing cancer aggressiveness. We establish periostin as a stromal marker of chemotherapeutic activity intrinsically upregulated in consensus molecular subtype 4 (CMS4) tumors and highly expressed before and/or after treatment in patients unresponsive to therapy. Collectively, our study underscores the ability of CT-retaining CAFs to support cancer progression and resistance to treatment.This work has been supported by grants from Fundación científica AECC -Asociación Española contra el Cáncer- (GCAEC20030CERV) to A.Ce., from Instituto de Salud Carlos III (ISCIII) co-funded by the European Union (CP16/00151, PI17/00211, PI20/00011; Spanish Ministry of Economy and Competitiveness) to A.Ca. and PI20/00625 to P.N., from la Caixa Foundation (LCF/PR/HR19/52160018) and MICINN (PID2020- 119917RB-I00) to E.B., from Spanish Ministerio de Economia y Competitividad (MINECO) and FEDER funds (PID2019-104948RB-I00) to R.R.G. This work was supported by Grant PT20/00023, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, and the Xarxa de Bancs de tumors sponsored by Pla Director d’Oncologia de Catalunya (XBTC). A.Ca. is the recipient of funding from the Instituto de Salud Carlos III co-funded by the European Union (MS16/00151; CPII21/00012). J.L. is the recipient of a Junior Clinician fellowship from Fundación científica AECC (CLJUN19004LINA)

Desensitization to Warfarin in Patients with Thromboembolic Pathologies

Las patologías tromboembólicas se encuentran entre las enfermedades vasculares más frecuentes&nbsp; en la mayoría de los países. La piedra angular del tratamiento ETV actualmente es la anticoagulación, entre los fármacos más utilizados está la warfarina. La Warfarina ha sido utilizada tradicionalmente como anticoagulante oral para la profilaxis y el tratamiento de ETV; sin embargo, tiene limitaciones como la hipersensibilidad a este fármaco, lento inicio de acción, riesgo de hemorragia, necrosis de piel, alopecia, y necesidad de monitoreo riguroso. Pese a sus efectos adversos, la warfarina es un anticoagulante que evita la actividad de los factores de coagulación dependientes de la vitamina K,&nbsp; es por ello que la desensibilización a la warfarina representa un desafío clínico significativo en pacientes con patologías tromboembólicas, particularmente cuando se enfrentan a complicaciones hemorrágicas o intolerancia a la terapia anticoagulante convencional. El objetivo de este artículo es reconocer la desensibilización a la warfarina en pacientes con patologías tromboembólicas.Thromboembolic pathologies are among the most common vascular diseases in most countries. The cornerstone of ETV treatment currently is anticoagulation, among the most used drugs is warfarin. Warfarin has traditionally been used as an oral anticoagulant for the prophylaxis and treatment of VTE; However, it has limitations such as hypersensitivity to this drug, slow onset of action, risk of hemorrhage, skin necrosis, alopecia, and the need for rigorous monitoring. Despite its adverse effects, warfarin is an anticoagulant that prevents the activity of vitamin K-dependent coagulation factors, which is why desensitization to warfarin represents a significant clinical challenge in patients with thromboembolic pathologies, particularly when faced with to bleeding complications or intolerance to conventional anticoagulant therapy. The objective of this article is to recognize warfarin desensitization in patients with thromboembolic pathologies

Safety and preliminary efficacy on cognitive performance and adaptive functionality of epigallocatechin gallate (EGCG) in children with Down syndrome. A randomized phase Ib clinical trial (PERSEUS study)

Purpose: Although some caregivers are using epigallocatechin gallate (EGCG) off label in hopes of improving cognition in young adults with Down syndrome (DS), nothing is known about its safety, tolerability, and efficacy in the DS pediatric population. We aimed to evaluate safety and tolerability of a dietary supplement containing EGCG and if EGCG improves cognitive and functional performance. Methods: A total of 73 children with DS (aged 6-12 years) were randomized. Participants received 0.5% EGCG (10 mg/kg daily dose) or placebo for 6 months with 3 months follow up after treatment discontinuation. Results: In total, 72 children were treated and 66 completed the study. A total of 38 participants were included in the EGCG group and 35 in the placebo group. Of 72 treated participants, 62 (86%) had 229 treatment-emergent adverse events (AEs). Of 37 participants in the EGCG group, 13 (35%) had 18 drug-related treatment-emergent AEs and 12 of 35 (34%) from the placebo group had 22 events. In the EGCG group, neither severe AEs nor increase in the incidence of AEs related to safety biomarkers were observed. Cognition and functionality were not improved compared with placebo. Secondary efficacy outcomes in girls point to a need for future work. Conclusion: The use of EGCG is safe and well-tolerated in children with DS, but efficacy results do not support its use in this population. (C) 2022 The Authors. Published by Elsevier Inc. on behalf of American College of Medical Genetics and Genomics

CIBERER : Spanish national network for research on rare diseases: A highly productive collaborative initiative

Altres ajuts: Instituto de Salud Carlos III (ISCIII); Ministerio de Ciencia e Innovación.CIBER (Center for Biomedical Network Research; Centro de Investigación Biomédica En Red) is a public national consortium created in 2006 under the umbrella of the Spanish National Institute of Health Carlos III (ISCIII). This innovative research structure comprises 11 different specific areas dedicated to the main public health priorities in the National Health System. CIBERER, the thematic area of CIBER focused on rare diseases (RDs) currently consists of 75 research groups belonging to universities, research centers, and hospitals of the entire country. CIBERER's mission is to be a center prioritizing and favoring collaboration and cooperation between biomedical and clinical research groups, with special emphasis on the aspects of genetic, molecular, biochemical, and cellular research of RDs. This research is the basis for providing new tools for the diagnosis and therapy of low-prevalence diseases, in line with the International Rare Diseases Research Consortium (IRDiRC) objectives, thus favoring translational research between the scientific environment of the laboratory and the clinical setting of health centers. In this article, we intend to review CIBERER's 15-year journey and summarize the main results obtained in terms of internationalization, scientific production, contributions toward the discovery of new therapies and novel genes associated to diseases, cooperation with patients' associations and many other topics related to RD research